Nobel Biocare extends syndicated loan facility

Nobel Biocare announced today the extension of its existing EUR 330 million committed syndicated banking facility for 5 years (through 2015). Besides the extension, Nobel Biocare was able to improve the implied funding terms in the new facility, which was done with the same 6 international banks as with the original line.
Dirk Kirsten, Chief Financial Officer, said: “The amendment and extension of the existing line reflects Nobel Biocare's continued balance sheet strength and its ability to generate a positive cash flow even in a difficult economic environment. Furthermore, the facility also supports our financial flexibility going forward. I am pleased that the same 6 banks have reconfirmed their commitment for a longer period.”